Full Text Journal Articles by
Author Tsugiko Oze

Advertisement

Find full text journal articles






Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.

Ryoko Yamada, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Naoki Morishita, Takahiro Kodama, Hayato Hikita, Ryotaro Sakamori, Takayuki Yakushijin, Akira Yamada, Hideki Hagiwara, Eiji Mita, Masahide Oshita, Toshifumi Itoh, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Atsuo Inoue, Yasuharu Imai, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(5):570-578]

Cited: 7 times

View full text PDF listing >>



Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.

Yugo Kai, Hayato Hikita, Naoki Morishita, Kazuhiro Murai, Tasuku Nakabori, Sadaharu Iio, Hideki Hagiwara, Yasuharu Imai, Shinji Tamura, Syusaku Tsutsui, Masafumi Naito, Meiko Nishiuchi, Yasuteru Kondo, Takanobu Kato, Hiroshi Suemizu, Ryoko Yamada, Tsugiko Oze, Takayuki Yakushijin, Naoki Hiramatsu, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara,

Resistance-associated substitutions (RASs) in hepatitis C virus (HCV) appear upon failure of treatment with direct-acting antivirals (DAAs). However, their origin has not been clarified in detail. Among 11 HCV genotype 1b patients who experienced virologic failure with asunaprevir (ASV)/daclatasvir (DCV), 10 had major NS5A L31M/V-Y93H variants after treatment. L31M/V-Y93H variants ... Read more >>

Sci Rep (Scientific reports)
[2017, 7:41660]

Cited: 12 times

View full text PDF listing >>



Advertisement

Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.

Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Sadaharu Iio, Akira Yamada, Hideki Hagiwara, Eiji Mita, Yukinori Yamada, Toshifumi Ito, Masami Inada, Kazuhiro Katayama, Iwao Yabuuchi, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>Simeprevir (SMV)-based triple therapy is an effective retreatment option following failure of telaprevir (TVR)-based triple therapy. However, it is unclear whether the persistence of resistance-associated variants (RAVs) induced by TVR-based therapy may reduce the treatment effect of SMV-based therapy.<h4>Methods</h4>The factors associated with the treatment effect, including RAVs in the NS3 ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2017, 47(8):773-782]

Cited: 2 times

View full text PDF listing >>



Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yukinori Yamada, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

The factors associated with sustained virologic response (SVR) in chronic hepatitis C (CH-C) genotype 1 patients treated with simeprevir (SMV), pegylated interferon (Peg-IFN) plus ribavirin (RBV) triple therapy have not been fully investigated. Two hundred and twenty-nine treatment-naïve CH-C patients treated with SMV triple therapy were enrolled in this study. ... Read more >>

J Med Virol (Journal of medical virology)
[2016, 88(10):1776-1784]

Cited: 1 time

View full text PDF listing >>



[Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C].

Naoki Hiramatsu, Tsugiko Oze,

Nihon Rinsho (Nihon rinsho. Japanese journal of clinical medicine)
[2015, 73 Suppl 9:238-242]

Cited: 0 times

View full text PDF listing >>



The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita, Naoki Harada, Ryoko Yamada, Takayuki Yakushijin, Eiji Mita, Hideki Hagiwara, Yukinori Yamada, Toshifumi Ito, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Keiko Irishio, Michio Kato, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>Hyperbilirubinemia, mild or moderate, is a commonly observed laboratory abnormality in chronic hepatitis C patients treated with simeprevir with pegylated interferon (Peg-IFN) plus ribavirin. In this prospective, multicenter study, we aimed to investigate the clinical features and factors associated with bilirubin increases during the therapy.<h4>Methods</h4>A total of 192 patients with ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2016, 51(3):252-259]

Cited: 7 times

View full text PDF listing >>



Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.

Yugo Kai, Hayato Hikita, Tomohide Tatsumi, Tasuku Nakabori, Yoshinobu Saito, Naoki Morishita, Satoshi Tanaka, Takatoshi Nawa, Tsugiko Oze, Ryotaro Sakamori, Takayuki Yakushijin, Naoki Hiramatsu, Hiroshi Suemizu, Tetsuo Takehara,

<h4>Background</h4>Resistance-associated variants (RAVs) emerge at multiple positions spanning hepatitis C virus (HCV) NS3/4A and NS5A regions upon failure of asunaprevir/daclatasvir combination therapy. It has not been determined whether the emergence of such RAVs have an impact on re-treatment by a combination of ledipasvir and sofosbuvir, a potent regimen for HCV ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2015, 50(11):1145-1151]

Cited: 20 times

View full text PDF listing >>



Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.

Naoki Harada, Naoki Hiramatsu, Tsugiko Oze, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

The use of pegylated interferon (Peg-IFN) plus ribavirin combination therapy for chronic hepatitis C patients who received curative treatment for hepatocellular carcinoma is controversial. This study tried to clarify this. Ninety-nine chronic hepatitis C patients who received curative resection or radiofrequency ablation for primary hepatocellular carcinoma, met the Milan criteria ... Read more >>

J Med Virol (Journal of medical virology)
[2015, 87(7):1199-1206]

Cited: 5 times

View full text PDF listing >>



Erratum to: Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis.

Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Naoki Harada, Ryoko Yamada, Masanori Miyazaki, Takayuki Yakushijin, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Tetsuo Takehara,

J Gastroenterol (Journal of gastroenterology)
[2015, 50(6):705]

Cited: 1 time

View full text PDF listing >>



[Pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C].

Tsugiko Oze, Naoki Hiramatsu, Tetsuo Takehara,

The antiviral therapy for patients with chronic hepatitis C virus(HCV) infection has changed from interferon(IFN) monotherapy to dual therapy with IFN plus ribavirin(RBV), moreover pegylated IFN(Peg-IFN) plus RBV. The sustained virologic response(SVR), defined as HCV RNA negativiation at 24 weeks after the treatment, were obtained 50% among the patients with ... Read more >>

Nihon Rinsho (Nihon rinsho. Japanese journal of clinical medicine)
[2015, 73(2):249-258]

Cited: 0 times

View full text PDF listing >>



Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.

Naoki Hiramatsu, Tsugiko Oze, Tetsuo Takehara,

The advance of antiviral treatment for chronic hepatitis C has brought a high sustained virological response (SVR) rate. In this review article, the suppressive effect of interferon (IFN)-based therapy on the development of hepatocellular carcinoma (HCC), risk factors for developing HCC and the characteristics of HCC development after SVR among ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2015, 45(2):152-161]

Cited: 32 times

View full text PDF listing >>



The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Ryoko Yamada, Naoki Harada, Naoki Morishita, Akira Yamada, Masahide Oshita, Akira Kaneko, Kunio Suzuki, Yoshiaki Inui, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>Triple therapy with telaprevir (TVR), pegylated interferon and ribavirin has improved antiviral efficacy in patients with chronic hepatitis C (CH-C). However, the severe adverse effects caused by TVR are important to resolve. In this prospective, randomized, multicenter, open-label study, the antiviral efficacy and safety in the reduced administration of TVR ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2015, 50(3):313-322]

Cited: 2 times

View full text PDF listing >>



Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Akinori Kasahara, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara, ,

<h4>Background & aims</h4>In patients with chronic hepatitis C virus (HCV) infection, lack of sustained virologic response (SVR) 24 weeks after the end of interferon therapy is a significant risk factor for hepatocellular carcinoma (HCC). Although many pretreatment factors are known to affect HCC incidence, less is known about post-treatment factors-many ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2014, 12(7):1186-1195]

Cited: 47 times

View full text PDF listing >>



Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.

Ryoko Yamada, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita, Naoki Harada, Masanori Miyazaki, Takayuki Yakushijin, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Norio Hayashi, Tetsuo Takehara,

The degree of liver fibrosis is strongly associated with the antiviral effect of interferon on chronic hepatitis C patients. In this study, the accuracy of acoustic radiation force impulse (ARFI) in assessing liver fibrosis and the association between liver stiffness using ARFI and antiviral effects were investigated. The 124 patients ... Read more >>

J Med Virol (Journal of medical virology)
[2014, 86(2):241-247]

Cited: 6 times

View full text PDF listing >>



Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C.

Kazuto Fukuda, Yasuharu Imai, Naoki Hiramatsu, Keiko Irishio, Takumi Igura, Yoshiyuki Sawai, Sachiyo Kogita, Yuki Makino, Rui Mizumoto, Yasushi Matsumoto, Masanori Nakahara, Sinichiro Zushi, Nobuyuki Kajiwara, Tsugiko Oze, Sumio Kawata, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>Renal damage has been reported as an important complication during combination treatment of peginterferon (PEG IFN), ribavirin (RBV) and telaprevir (TVR) for chronic hepatitis C. However, very little is known about this complication. We investigated the role TVR plays in renal damage during this triple therapy.<h4>Methods</h4>Twenty-five chronic hepatitis C patients ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2014, 44(12):1165-1171]

Cited: 6 times

View full text PDF listing >>



Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis.

Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Naoki Harada, Ryoko Yamada, Masanori Miyazaki, Takayuki Yakushijin, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Tetsuo Takehara,

<h4>Background</h4>Screening and periodic surveillance for esophageal varices (EVs) by esophagogastroduodenoscopy (EGD) are recommended for cirrhotic patients. We investigated non-invasive liver stiffness measurement using acoustic radiation force impulse (ARFI) for the diagnosis of EV presence and high-risk EVs among patients with HCV-related cirrhosis.<h4>Methods</h4>Among 181 consecutive patients with HCV-related cirrhosis, we studied ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2014, 49(7):1175-1182]

Cited: 17 times

View full text PDF listing >>



Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Sadaharu Iio, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>HCV kinetics during treatment demonstrated strong association with the antiviral outcome of patients treated with pegylated interferon (Peg-IFN) plus ribavirin. However, the relationship between HCV kinetics and pre-treatment factors remains unclear.<h4>Methods</h4>Of 547 patients with HCV genotype 1 treated with Peg-IFN alfa-2b plus ribavirin, 401 completed the response-guided therapy and were ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2014, 49(4):737-747]

Cited: 3 times

View full text PDF listing >>



A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.

Tsugiko Oze, Naoki Hiramatsu, Eiji Mita, Norio Akuta, Naoya Sakamoto, Hiroaki Nagano, Yoshito Itoh, Shuichi Kaneko, Namiki Izumi, Hideyuki Nomura, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>  This study aimed to clarify the factors associated the efficacy of re-treatment with pegylated interferon (PEG IFN) plus ribavirin combination therapy for patients with chronic hepatitis C who had failed to respond to previous treatment.<h4>Methods</h4>  One hundred and forty-three patients who had previously shown relapse (n = 79), non-response (n = 34) or ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2013, 43(1):35-43]

Cited: 7 times

View full text PDF listing >>



Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.

Koyo Higashitani, Tatsuya Kanto, Shoko Kuroda, Sachiyo Yoshio, Tokuhiro Matsubara, Naruyasu Kakita, Tsugiko Oze, Masanori Miyazaki, Mitsuru Sakakibara, Naoki Hiramatsu, Eiji Mita, Yasuharu Imai, Akinori Kasahara, Alato Okuno, Osamu Takikawa, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>Altered functions of dendritic cells (DCs) and/or increases of regulatory T cells (Tregs) are involved in the pathogenesis of chronic hepatitis C virus (HCV) infection. A tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO), is reported to be an inducer of immune tolerance. Our aim was to clarify whether or not IDO is ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2013, 48(5):660-670]

Cited: 25 times

View full text PDF listing >>



Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma.

Keisuke Kohga, Tomohide Tatsumi, Hinako Tsunematsu, Satoshi Aono, Satoshi Shimizu, Takahiro Kodama, Hayato Hikita, Masashi Yamamoto, Tsugiko Oze, Hiroshi Aketa, Atsushi Hosui, Takuya Miyagi, Hisashi Ishida, Naoki Hiramatsu, Tatsuya Kanto, Norio Hayashi, Tetsuo Takehara,

The production of soluble major histocompatibility complex class I-related chain A (MICA) is thought to antagonize NKG2D-mediated immunosurveillance. Interleukin-1β (IL-1β) is elevated in patients with chronic hepatitis C (CH), and this might contribute to the escape of hepatocellular carcinoma (HCC) cells from innate immunity. In this study, we investigated the ... Read more >>

Cancer Immunol Immunother (Cancer immunology, immunotherapy : CII)
[2012, 61(9):1425-1432]

Cited: 10 times

View full text PDF listing >>



Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.

Naoki Harada, Naoki Hiramatsu, Tsugiko Oze, Ryoko Yamada, Mika Kurokawa, Masanori Miyazaki, Takayuki Yakushijin, Takuya Miyagi, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Masahide Oshita, Eiji Mita, Hideki Hagiwara, Yoshiaki Inui, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Atsuo Inoue, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>This study was conducted to evaluate Japanese treatment guidelines for patients with chronic hepatitis C virus (HCV) infection and normal alanine aminotransferase (N-ALT) levels from the viewpoint of the incidence of hepatocellular carcinoma (HCC).<h4>Methods</h4>Four groups of patients with chronic HCV infection treated with pegylated interferon (Peg-IFN) plus ribavirin, and classified ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2013, 48(4):535-543]

Cited: 2 times

View full text PDF listing >>



Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.

Naoki Hiramatsu, Yuko Inoue, Tsugiko Oze, Nao Kurashige, Takayuki Yakushijin, Kiyoshi Mochizuki, Takuya Miyagi, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Masahide Oshita, Eiji Mita, Hideki Hagiwara, Yoshiaki Inui, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Norio Hayashi,

<h4>Background</h4>The antiviral effect of pegylated interferon (Peg-IFN) plus ribavirin combination therapy in chronic hepatitis C (CHC) patients with normal alanine aminotransferase (ALT) levels (N-ALT) has been reported to be equivalent to that for patients with elevated ALT levels (E-ALT). However, the actual antiviral effect in N-ALT patients remains obscure because ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2011, 46(11):1335-1343]

Cited: 6 times

View full text PDF listing >>



Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.

Tsugiko Oze, Naoki Hiramatsu, Changho Song, Takayuki Yakushijin, Sadaharu Iio, Yoshinobu Doi, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Masanori Miyazaki, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>The timing to the first undetectable hepatitis C virus (HCV) RNA level is strongly associated with sustained virologic response in pegylated interferon (Peg-IFN) plus ribavirin combination therapy for patients with chronic hepatitis C (CH-C) with genotype 1. This study was conducted to clarify the impact of drug exposure to Peg-IFN ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2012, 47(3):334-342]

Cited: 2 times

View full text PDF listing >>



[Development of anti viral therapy for chronic hepatitis type C].

Norio Hayashi, Tsugiko Oze, Naoki Hiramatsu,

Nihon Rinsho (Nihon rinsho. Japanese journal of clinical medicine)
[2011, 69 Suppl 4:173-179]

Cited: 0 times

View full text PDF listing >>



Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.

Tatsuya Kanto, Michiyo Inoue, Tsugiko Oze, Masanori Miyazaki, Mitsuru Sakakibara, Naruyasu Kakita, Tokuhiro Matsubara, Koyo Higashitani, Hideki Hagiwara, Sadaharu Iio, Kazuhiro Katayama, Eiji Mita, Akinori Kasahara, Naoki Hiramatsu, Tetsuo Takehara, Norio Hayashi,

<h4>Background</h4>For the treatment of chronic hepatitis C, a combination of pegylated interferon-α (PEG-IFNα) and ribavirin has been widely used as a standard of care. Enhancement of immune response against hepatitis C virus (HCV) is known to be involved in the efficacy of the combination therapy. Our aim was to elucidate ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2012, 47(2):169-178]

Cited: 8 times

View full text PDF listing >>



Advertisement


Disclaimer

1.3698 s